Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency in the United States and Canada. Its clinical-stage product candidates are Recorlev, a cortisol synthesis inhibitor, which is in a Phase III clinical trial that is used for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that is used for treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is headquartered in Trevose, Pennsylvania.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SBBP
CUSIPN/A
Phone610-254-9200
Debt
Debt-to-Equity Ratio8.76
Current Ratio6.46
Quick Ratio6.38
Price-To-Earnings
Trailing P/E Ratio-3.45
Forward P/E Ratio-2.73
P/E GrowthN/A
Sales & Book Value
Annual Sales$7.05 million
Price / Sales32.60
Cash FlowN/A
Price / CashN/A
Book Value($0.30) per share
Price / Book-16.40
Profitability
EPS (Most Recent Fiscal Year)($1.45)
Net Income$-113,480,000.00
Net Margins-624.52%
Return on EquityN/A
Return on Assets-46.22%
Miscellaneous
Employees66
Outstanding Shares46,710,000
Market Cap$226.54 million
Strongbridge Biopharma (NASDAQ:SBBP) Frequently Asked Questions
What is Strongbridge Biopharma's stock symbol?
Strongbridge Biopharma trades on the NASDAQ under the ticker symbol "SBBP."
How were Strongbridge Biopharma's earnings last quarter?
Strongbridge Biopharma plc (NASDAQ:SBBP) announced its quarterly earnings results on Wednesday, August, 8th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.47) by $0.41. The biotechnology company earned $4.30 million during the quarter, compared to the consensus estimate of $4.53 million. View Strongbridge Biopharma's Earnings History.
When is Strongbridge Biopharma's next earnings date?
What price target have analysts set for SBBP?
4 brokerages have issued 12-month price objectives for Strongbridge Biopharma's shares. Their forecasts range from $16.00 to $18.00. On average, they anticipate Strongbridge Biopharma's stock price to reach $16.75 in the next twelve months. This suggests a possible upside of 240.4% from the stock's current price. View Analyst Price Targets for Strongbridge Biopharma.
What is the consensus analysts' recommendation for Strongbridge Biopharma?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Strongbridge Biopharma in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Strongbridge Biopharma.
What are Wall Street analysts saying about Strongbridge Biopharma stock?
Here are some recent quotes from research analysts about Strongbridge Biopharma stock:
- 1. According to Zacks Investment Research, "Strongbridge Biopharma PLC is a biopharmaceutical company which develops, acquires and commercializes product candidates that target rare diseases. Its product candidate consists of COR-003, is a cortisol inhibitor, for the treatment of endogenous Cushing's syndrome, COR-004 and COR-005 to treat acromegaly, BP-2001, the treatment of diabetes which are in different clinical trial. Strongbridge Biopharma PLC is based in Trevose, Pennsylvania. " (8/16/2018)
- 2. HC Wainwright analysts commented, "BioLife reported 1Q18 biopreservation media revenue of $3.8, up 22% sequentially and 61% y/y. Margin also continue to rise with increasing volume, coming in at 64% in 1Q. The company is cash flow positive and currently has $9.6M in cash on the balance sheet (including $2.6M from warrants exercised recently). Biolife’s valuation continues to rise as media revenue grows and the company becomes more deeply integrated into an evolving cell therapy space. We are increasing our outyear estimates for cell media revenue which increases our 12-month price target to $12, from $9.." (5/11/2018)
- 3. Cantor Fitzgerald analysts commented, "Added Focus on RECORLEV into Mid-2108. Ahead of the mid-2018 SONICS top-line readout, we anticipate greater attention to shift towards the RECORLEV opportunity in Cushing’s syndrome. As a reminder, we believe Recorlev has demonstrated greater control over cortisol secretion over ketoconazole with fewer liabilities associated with liver enzyme elevations. Strongbridge plans to host an investor and analyst day on April 5, 2018, to discuss these opportunities and development progress. Following SONICS we anticipate data from LOGICS in 1Q19, a slight slippage from 4Q18, previously." (3/12/2018)
Are investors shorting Strongbridge Biopharma?
Strongbridge Biopharma saw a decrease in short interest in September. As of September 28th, there was short interest totalling 709,338 shares, a decrease of 34.0% from the September 14th total of 1,075,149 shares. Based on an average daily trading volume, of 498,809 shares, the days-to-cover ratio is currently 1.4 days. Approximately 1.9% of the shares of the stock are sold short. View Strongbridge Biopharma's Current Options Chain.
Who are some of Strongbridge Biopharma's key competitors?
Some companies that are related to Strongbridge Biopharma include MacroGenics (MGNX), Amphastar Pharmaceuticals (AMPH), Homology Medicines (FIXX), CytomX Therapeutics (CTMX), Radius Health (RDUS), Inflarx (IFRX), NuCana (NCNA), Dynavax Technologies (DVAX), Insys Therapeutics (INSY), ProQR Therapeutics (PRQR), Epizyme (EPZM), Flexion Therapeutics (FLXN), AMAG Pharmaceuticals (AMAG), Crinetics Pharmaceuticals (CRNX) and ANI Pharmaceuticals (ANIP).
Who are Strongbridge Biopharma's key executives?
Strongbridge Biopharma's management team includes the folowing people:
- Mr. Matthew Pauls, CEO, Pres & Director (Age 47)
- Mr. A. Brian Davis, Chief Financial Officer (Age 51)
- Dr. Fredric Cohen, Chief Medical Officer (Age 53)
- Dr. Per Marin M.D., Ph.D., Founder and Sr. Clinical Advisor
- Mr. Peter J. Valentinsson, Sr. VP of Global Technical Operations
Who are Strongbridge Biopharma's major shareholders?
Which institutional investors are buying Strongbridge Biopharma stock?
How do I buy shares of Strongbridge Biopharma?
Shares of SBBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Strongbridge Biopharma's stock price today?
One share of SBBP stock can currently be purchased for approximately $4.92.
How big of a company is Strongbridge Biopharma?
Strongbridge Biopharma has a market capitalization of $226.54 million and generates $7.05 million in revenue each year. The biotechnology company earns $-113,480,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis. Strongbridge Biopharma employs 66 workers across the globe.
What is Strongbridge Biopharma's official website?
How can I contact Strongbridge Biopharma?
Strongbridge Biopharma's mailing address is 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053. The biotechnology company can be reached via phone at 610-254-9200 or via email at [email protected]
MarketBeat Community Rating for Strongbridge Biopharma (NASDAQ SBBP)
MarketBeat's community ratings are surveys of what our community members think about Strongbridge Biopharma and other stocks. Vote "Outperform" if you believe SBBP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SBBP will underperform the S&P 500 over the long term. You may vote once every thirty days.
